Releases › HCPCS Level II April 2024
HCPCS Level II April 2024
Effective 2024-04-01 to 2024-06-30. 8,349 codes in the release.
64added
14revised
19removed
Codes added 64
| Code | Description |
|---|---|
| A2026 | Restrata minimatrix, 5 mg |
| A4271 | Integrated lancing and blood sample testing cartridges for home blood glucose monitor, per month |
| A4438 | Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each |
| A4564 | Pessary, disposable, any type |
| A4593 | Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller |
| A4594 | Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each |
| A9293 | Fertility cycle (contraception & conception) tracking software application, fda cleared, per month, includes accessories (e.g., thermometer) |
| C9166 | Injection, secukinumab, intravenous, 1 mg |
| C9167 | Injection, adamts13, recombinant-krhn, 10 iu |
| C9168 | Injection, mirikizumab-mrkz, 1 mg |
| C9796 | Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with plug (e.g., porcine small intestine submucosa [sis]) |
| C9797 | Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction |
| E0152 | Walker, battery powered, wheeled, folding, adjustable or fixed height |
| E0468 | Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation, includes all accessories, components and supplies for all functions |
| E0736 | Transcutaneous tibial nerve stimulator |
| E0738 | Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories |
| E0739 | Rehab system with interactive interface providing active assistance in rehabilitation therapy, includes all components and accessories, motors, microprocessors, sensors |
| E2104 | Home blood glucose monitor for use with integrated lancing/blood sample testing cartridge |
| E2298 | Complex rehabilitative power wheelchair accessory, power seat elevation system, any type |
| G0138 | Intravenous infusion of cipaglucosidase alfa-atga, including provider/supplier acquisition and clinical supervision of oral administration of miglustat in preparation of receipt of cipaglucosidase alfa-atga |
| H0051 | Traditional healing service |
| J0177 | Injection, aflibercept hd, 1 mg |
| J0209 | Injection, sodium thiosulfate (hope), 100 mg |
| J0577 | Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy |
| J0578 | Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy |
| J0589 | Injection, daxibotulinumtoxina-lanm, 1 unit |
| J0650 | Injection, levothyroxine sodium, not otherwise specified, 10 mcg |
| J0651 | Injection, levothyroxine sodium (fresenius kabi) not therapeutically equivalent to j0650, 10 mcg |
| J0652 | Injection, levothyroxine sodium (hikma) not therapeutically equivalent to j0650, 10 mcg |
| J1010 | Injection, methylprednisolone acetate, 1 mg |
| J1202 | Miglustat, oral, 65 mg |
| J1203 | Injection, cipaglucosidase alfa-atga, 5 mg |
| J1323 | Injection, elranatamab-bcmm, 1 mg |
| J1434 | Injection, fosaprepitant (focinvez), 1 mg |
| J2277 | Injection, motixafortide, 0.25 mg |
| J2782 | Injection, avacincaptad pegol, 0.1 mg |
| J2801 | Injection, risperidone (rykindo), 0.5 mg |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg |
| J3055 | Injection, talquetamab-tgvs, 0.25 mg |
| J3424 | Injection, hydroxocobalamin, intravenous, 25 mg |
| J7165 | Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity |
| J7354 | Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg) |
| J9073 | Injection, cyclophosphamide (ingenus), 5 mg |
| J9074 | Injection, cyclophosphamide (sandoz), 5 mg |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg |
| J9248 | Injection, melphalan (hepzato), 1 mg |
| J9249 | Injection, melphalan (apotex), 1 mg |
| J9376 | Injection, pozelimab-bbfg, 1 mg |
| K1037 | Docking station for use with oral device/appliance used to reduce upper airway collapsibility |
| L1320 | Thoracic, pectus carinatum orthosis, sternal compression, rigid circumferential frame with anterior and posterior rigid pads, custom fabricated |
| L5783 | Addition to lower extremity, user adjustable, mechanical, residual limb volume management system |
| L5841 | Addition, endoskeletal knee-shin system, polycentric, pneumatic swing, and stance phase control |
| M0224 | Intravenous infusion, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, includes infusion and post administration monitoring |
| Q0224 | Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg |
| Q4305 | American amnion ac tri-layer, per square centimeter |
| Q4306 | American amnion ac, per square centimeter |
| Q4307 | American amnion, per square centimeter |
| Q4308 | Sanopellis, per square centimeter |
| Q4309 | Via matrix, per square centimeter |
| Q4310 | Procenta, per 100 mg |
| Q5133 | Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg |
| Q5134 | Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg |
| S4988 | Penile contracture device, manual, greater than 3 lbs traction force |
| S9002 | Intra-vaginal motion sensor system, provides biofeedback for pelvic floor muscle rehabilitation device |
Descriptions revised 14
| Code | Was, and is now |
|---|---|
| A4561 | |
| A4562 | |
| E2001 | |
| J0208 | |
| J0612 | |
| J0613 | |
| J3380 | |
| J3425 | |
| J7516 | |
| J9029 | |
| J9071 | |
| J9072 | |
| J9255 | |
| J9260 |
Terminated 19
| Code | Description |
|---|---|
| C9159 | Injection, prothrombin complex concentrate (human), balfaxar, per i.u. of factor ix activity |
| C9160 | Injection, daxibotulinumtoxina-lanm, 1 unit |
| C9161 | Injection, aflibercept hd, 1 mg |
| C9162 | Injection, avacincaptad pegol, 0.1 mg |
| C9163 | Injection, talquetamab-tgvs, 0.25 mg |
| C9164 | Cantharidin for topical administration, 0.7%, single unit dose applicator (3.2 mg) |
| C9165 | Injection, elranatamab-bcmm, 1 mg |
| E2300 | Wheelchair accessory, power seat elevation system, any type |
| J0576 | Injection, buprenorphine extended-release (brixadi), 1 mg |
| J1020 | Injection, methylprednisolone acetate, 20 mg |
| J1030 | Injection, methylprednisolone acetate, 40 mg |
| J1040 | Injection, methylprednisolone acetate, 80 mg |
| J1840 | Injection, kanamycin sulfate, up to 500 mg |
| J1850 | Injection, kanamycin sulfate, up to 75 mg |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg |
| J9070 | Cyclophosphamide, 100 mg |
| J9250 | Methotrexate sodium, 5 mg |
| Q4244 | Procenta, per 200 mg |